EU-funded project to simplify and enhance the analysis of Lumito's image data

Lumito AB (publ) (“Lumito” or the “Company”) has been granted 320 hours of expert support through the EU-funded DataCatalyst Öresund project. The support will be used to develop a tailored extension for the QuPath image-analysis platform, making it easier to work with Lumito's image data while giving researchers and drug developers more powerful analytical tools in their existing workflows.

For Lumito, the initiative is part of its strategy to simplify the integration of SCIZYS® into established analysis environments and thereby support wider use among researchers and drug developers.

Lumito's image data can already be used in QuPath. The project will take the next step by simplifying import, management and analysis. The extension will also give users more powerful tools for efficient, advanced image analysis in an environment familiar to many potential customers. The expert support is funded through the EU's the Interreg Öresund-Kattegat-Skagerrak programme.

“For our customers, the value lies not only in the image information our technology provides, but also in how easily and efficiently the results can be evaluated in day-to-day work. By making our images easier to analyse in QuPath, we want to lower the barrier for new users while providing more experienced users with more powerful tools. This helps create the conditions for wider use of our technology,” says Sanna Wallenborg, CEO of Lumito.

From image information to customer value
Lumito's technology generates detailed imaging information from tissue samples that can be used to study biomarkers, disease mechanisms and treatment effects.

For the image information to deliver value, it must be easy to review and analyse using powerful tools. The planned QuPath extension will simplify workflows and provide expanded analytical capabilities directly within the environment users already work in.

Lowering barriers from initial testing to customer evaluation
For research organisations and pharmaceutical companies, adopting new technology may require training, new tools and changes to established working practices. By simplifying analysis in QuPath, Lumito aims to make it easier for potential customers to assess the technology's potential in their own operations. For the Company, this could mean a clearer offering in discussions with potential customers and a more straightforward path to more extensive testing.

Complementing Lumito's existing offering
The QuPath initiative will complement Lumito's existing visualisation and image-analysis solutions. Within the Company's Scan-as-a-Service offering, Lumito images can already be visualised through Katana Labs' cloud service. A tailored QuPath extension will give users another way to work with image data and may make the offering more flexible to meet different customer needs.

About QuPath
QuPath is an internationally established open-source software platform for visualising, analysing and quantifying digital tissue images. It is used by researchers, academic institutions and pharmaceutical companies.

About DataCatalyst Öresund
DataCatalyst Öresund is a cross-border collaborative project under the Interreg Öresund-Kattegat-Skagerrak programme that aims to strengthen companies' ability to turn data into innovation and business value. The project links companies' development needs with expertise in data management, analysis and visualisation. It runs from July 2026 to June 2029 and is led by Lund University in collaboration with the Technical University of Denmark and Medicon Valley Alliance.

About Lumito
Lumito develops and markets innovative technology that opens up new possibilities for advanced analysis of tissue samples in research, drug development and digital pathology.

The Company's patented SCIZYS® platform is based on upconverting nanoparticles (UCNPs) and combines very high detection sensitivity with minimal background interference. The technology enables the identification and quantitative analysis of specific proteins in tissue, even at low levels that may be difficult to detect using conventional methods. High signal stability and low background provide the basis for more detailed and reproducible tissue analysis.

SCIZYS® has the potential to support a shift from predominantly visual and semi-quantitative biomarker assessment to more sensitive, objective and quantitative analysis. This can provide researchers with new tools to understand disease mechanisms, identify biomarkers and develop more personalised treatment strategies.

Lumito's vision extends beyond current research applications. By providing more detailed information about biological processes, the Company aims to contribute to the development of precision medicine, in which better medicines, diagnostics and more informed treatment decisions may, over time, lead to improved patient outcomes and more efficient use of healthcare resources.

Lumito

Seeing more. Enabling precision medicine.
Shaping the future of patient care.

www.lumito.se

SCIZYS® is for research use only (RUO). Not for clinical or diagnostic use.

The share is traded on NGM Nordic SME under the name LUMITO.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

Attachments

EU-funded project to simplify and enhance the analysis of Lumito's image data